Autolus Therapeutics shares surge 35.48% premarket after NICE recommends AUCATZYL for NHS use in adult B-ALL patients.

Autolus Therapeutics surged 35.48% in premarket trading following the announcement that the UK’s NICE published draft guidance recommending its CAR-T therapy, AUCATZYL, for NHS use in treating adult relapsed or refractory B-cell acute lymphoblastic leukemia. The endorsement enables routine NHS commissioning, facilitating broader patient access and validating the therapy’s clinical value. This regulatory milestone, coupled with plans for an imminent UK launch, signals strong market expansion potential and bolsters confidence in Autolus’s commercial prospects. The news aligns with the stock’s upward trajectory, as the NICE recommendation addresses a critical unmet medical need and positions AUCATZYL as a key treatment option in a high-priority oncology indication.